bpc 157 disadvantages What is BPC-157? BPC-157 for Recovery Support –

Limitations: Primarily affects cornea and conjunctiva with minimal retinal penetration

However, preclinical data does not guarantee human safety

Zn homeostasis is facilitated by the SLC39/ZIP and SLC30/ZnT families of solute carrier proteins, which collectively distribute Zn with subcellular specificity

Injectable administration bypasses these problems and ensures the peptide reaches its target

When rats were dosed from gestational day 7 through weaning on postnatal day 21, a statistically significant decrease in maternal femur weight of up to 14% (as compared to placebo treatment) was observed at doses equal to or greater than 138 mg/kg/day (about 34 times an oral human dose of 40 mg on a body surface area basis)